Naldemedine + Placebo

ApprovedRecruiting

2 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Opioid-Induced Constipation (OIC)

Conditions

Opioid-Induced Constipation (OIC)

Trial Timeline

Jun 6, 2025 → Sep 30, 2027

NCT ID

NCT07038551

About Naldemedine + Placebo

Naldemedine + Placebo is a approved stage product being developed by Shionogi for Opioid-Induced Constipation (OIC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07038551. Target conditions include Opioid-Induced Constipation (OIC).

What happened to similar drugs?

3 of 20 similar drugs in Opioid-Induced Constipation (OIC) were approved

Approved (3) Terminated (8) Active (10)

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

❌NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07038551	Approved	Recruiting	Jun 6, 2025	Sep 30, 2027	Opioid-Induced Constipation (OIC)
NCT04355169	Phase 2	Terminated	Nov 6, 2020	Jan 4, 2021	Postoperative Gastrointestinal Dysfunction
NCT01993940	Phase 3	Completed	Nov 4, 2013	Jun 9, 2015	Opioid-induced Constipation
NCT01965652	Phase 3	Completed	Sep 24, 2013	Jan 12, 2016	Opioid-induced Constipation
NCT01965158	Phase 3	Completed	Aug 29, 2013	Jan 22, 2015	Opioid-induced Constipation
NCT01122030	Phase 2	Completed	May 19, 2010	Mar 22, 2011	Opioid Induced Bowel Dysfunction

Competing Products

20 competing products in Opioid-Induced Constipation (OIC)

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35
ALKS 37 + Placebo	Alkermes	Phase 2	32